<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303315</url>
  </required_header>
  <id_info>
    <org_study_id>MC CPTAN2010-017</org_study_id>
    <secondary_id>Position II</secondary_id>
    <nct_id>NCT01303315</nct_id>
  </id_info>
  <brief_title>TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy</brief_title>
  <official_title>TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetaCure (USA), Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetaCure (USA), Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the TANTALUS therapy in type 2 diabetic patients who can not tolerate GLP-1 agonist&#xD;
      due to unacceptable side effects; and to assess the TANTALUS therapy in type 2 diabetic&#xD;
      patients who do not sufficiently benefit from GLP-1 receptor agonist therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present protocol will address whether the effects of the TANTALUS treatment are&#xD;
      complimentary to GLP-1 treatment which is only partially effective or whether it can replace&#xD;
      GLP-1 treatment in individuals who cannot tolerate GLP-1 agonists because of unacceptable&#xD;
      side effects.&#xD;
&#xD;
      This investigation will be a 3 arm multicenter study which will enroll in a Run-In Period up&#xD;
      to 400 with type 2 diabetes mellitus. This Run-In Period will facilitate screening the&#xD;
      patients with the aim to have a maximum of 30 patients in each arm complete the Evaluation&#xD;
      Period of 6 months. The study aims at evaluating the TANTALUS therapy compared to GLP-1&#xD;
      receptor agonist therapy by evaluating improvement in glycemic control and weight after 6&#xD;
      months of treatment in each of the 3 study groups, which are:&#xD;
&#xD;
        -  Group A: subjects on GLP-1 receptor agonist therapy only&#xD;
&#xD;
        -  Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy&#xD;
&#xD;
        -  Group C: subjects on TANTALUS therapy only&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company strategic decision&#xD;
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrees in HbA1c of at least 0.5 points and Weight loss of at least 3% of total body weight after 6 month of treatment</measure>
    <time_frame>6 month</time_frame>
    <description>Change in HbA1c and weight will be assessed at baseline and 24 weeks of treatment for Group A and C.&#xD;
Additionally, each group will be analyzed for the weight of decrease extent, the percentage of patients achieving the endpoint, and the percentage of patients that reach an HbA1c less than 7.0%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic and metabolic parameters</measure>
    <time_frame>6 month</time_frame>
    <description>Glycemic Parameters (FBG, PPG)&#xD;
Glycemic Dynamics (Glucose, Insulin, C-Peptide, and Glucagon Profiles) via MTT&#xD;
Metabolic Parameters (WC, BP, Lipids, Gastric Emptying)&#xD;
Gastric Hormones (GLP-1, GIP, Ghrelin, PYY, Pancreatic Polypeptide) via MTT</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>GLP-1 receptor agonist therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group A: Subjects on GLP-1 receptor agonist therapy only. After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c &lt; 7.5 are moved to Group A, continue GLP-1 receptor agonist therapy, and then start the Evaluation Period These patients will not be implanted with the TANTALUS system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1 receptor agonist and TANTALUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c &gt; 7.5 are moved to Group B, continue GLP-1 receptor agonist therapy, implanted with TANTALUS within 4 weeks, and then start the Evaluation Period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects on TANTALUS therapy only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C: subjects on TANTALUS therapy only After run in of 12 weeks on GLP-1 receptor agonist therapy, patients intolerant to low dosage of GLP-1 receptor agonist therapy will be implanted with the TANTALUS system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TANTALUS System</intervention_name>
    <description>An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity</description>
    <arm_group_label>GLP-1 receptor agonist and TANTALUS</arm_group_label>
    <arm_group_label>GLP-1 receptor agonist therapy</arm_group_label>
    <arm_group_label>Subjects on TANTALUS therapy only</arm_group_label>
    <other_name>TANTALUS System, TANTALUS II</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects 21 through 70 years of age&#xD;
&#xD;
          2. Type 2 diabetes duration more than 6 months and less than 10 years&#xD;
&#xD;
          3. 7.8% &lt; HbA1c &lt; 10.5% if T2DM duration less than or equal to 5 years&#xD;
&#xD;
          4. 7.8% &lt; HbA1c &lt; 10.0% if T2DM duration more than 5 years&#xD;
&#xD;
          5. BMI &lt; 40 kg/m2&#xD;
&#xD;
          6. Taking at least one oral anti-diabetic medication&#xD;
&#xD;
          7. Patients treated with GLP-1 receptor agonist with at least one oral anti-diabetic&#xD;
             medication may be included under the following conditions:&#xD;
&#xD;
             a. The HbA1c, before GLP-1 receptor agonist therapy was administered, was: i. 7.8% &lt;&#xD;
             HbA1c &lt; 10.5% if T2DM duration less than 5 years ii. 7.8% &lt; HbA1c &lt; 10.0% if T2DM&#xD;
             duration greater than 5 years b. The patient was on GLP-1 receptor agonist therapy for&#xD;
             no more than 12 weeks&#xD;
&#xD;
          8. Women with childbearing potential (i.e., not post-menopausal or surgically sterilized)&#xD;
             must agree to use adequate birth control methods&#xD;
&#xD;
          9. If subject is taking lipid-lowering medication, the treatment must be stable for at&#xD;
             least one month prior to enrollment&#xD;
&#xD;
         10. If subject is taking anti-hypertensive medication, the treatment must be stable for at&#xD;
             least one month prior to enrollment&#xD;
&#xD;
         11. If subject is taking anti-depressant medication, the treatment must be stable for at&#xD;
             least one month prior to enrollment&#xD;
&#xD;
         12. Willingness to refrain from using prescription, over the counter, or herbal weight&#xD;
             loss products for the duration of the trial&#xD;
&#xD;
         13. Ability and willingness to perform required study and data collection procedures and&#xD;
             adhere to operating requirements of the TANTALUSÂ® System&#xD;
&#xD;
         14. Alert, mentally competent, and able to understand and willing to comply with the&#xD;
             requirements of the clinical trial, and personally motivated to abide by the&#xD;
             requirements and restrictions of the clinical trial&#xD;
&#xD;
         15. Able to provide voluntary informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Insulin therapy within the last 3 months 2. GLP-1 receptor agonist therapy longer than 3&#xD;
        months 3. Diagnosed with renal dysfunction or history of renal dysfunction 4. Taking&#xD;
        medications known to affect gastric motility 5. Use of prescription, over the counter or&#xD;
        herbal weight loss products or obesity drugs during the past two months 6. Experiencing&#xD;
        severe and progressing diabetic complications (7. Prior wound healing problems 8. Diagnosed&#xD;
        with past or current psychiatric condition that may impair his or her ability to comply&#xD;
        with the study procedures 9. Use of anti-psychotic medications 10. Diagnosed with eating&#xD;
        disorder such as bulimia or binge eating 11. Obesity due to an endocrinopathy 12. Hiatal&#xD;
        hernia requiring surgical repair or a paraesophageal hernia 13. Pregnant or lactating 14.&#xD;
        Diagnosed with impaired liver function 15. Any prior bariatric surgery 16. Any history of&#xD;
        pancreatitis 17. Any history of peptic ulcer disease within 5 years of enrollment 18.&#xD;
        Diagnosed with Gastroparesis or other GI motility disorder 19. Use of active medical&#xD;
        devices (either implantable or external) such as ICD, drug infusion device, or&#xD;
        neurostimulator (either implanted or worn). Subjects using an external active device who&#xD;
        are able and willing to avoid use of the device during the study may be enrolled.&#xD;
&#xD;
        20. Cardiac history that physician feels should exclude the subject from the study.&#xD;
&#xD;
        21. Use of another investigational device or agent in the 30 days prior to enrollment 22. A&#xD;
        history of life-threatening disease within 5 years of enrollment 23. Any additional&#xD;
        condition(s) that in the Investigator's opinion would warrant exclusion from the study or&#xD;
        prevent the subject from completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walid Haddad, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MetaCure Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fakultni Nemocnice U SV. Anny V Brne</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika gerontologickÃ¡ a metabolickÃ¡,</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital,</name>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prednosta OB Kliniky a.s.,</name>
      <address>
        <city>Prague</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Zentrum</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes-Praxis Muenster</name>
      <address>
        <city>MÃ¼nster</city>
        <zip>48153</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>'N. Paulescu' National Institute of Diabetes, Nutrition and Metabolic Diseases</name>
      <address>
        <city>Bucharest</city>
        <zip>79811</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMI Dr Busegeanu Mihaela Magdalena-Ploiesti</name>
      <address>
        <city>Bucharest</city>
        <zip>A</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Hospital - Surgical</name>
      <address>
        <city>Bucharest</city>
        <zip>A</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatatea Ta Medical Center</name>
      <address>
        <city>Bucharest</city>
        <zip>A</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sf. Ioan Hospital - Surgical</name>
      <address>
        <city>Bucharest</city>
        <zip>A</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Pelican, Orada</name>
      <address>
        <city>Bucharest</city>
        <zip>A</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>C19 246 300</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

